

Review on ICH Guideline for Aseptic Laboratory

Shejal A. Late¹, Kanchan R. Gaykar², Jagruti V. Kumbhar³

Students, Samarth College of Pharmacy, Belhe, Pune, Maharashtra, India^{1,2}

Student, Samarth Institute of Pharmacy, Belhe, Pune, Maharashtra, India³

Abstract: ICH Guidelines were created by The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH aims to provide uniform standards for technical requirements for pharmaceuticals for human use. They are developed by regulatory and pharma industry authorities. The purpose of ICH guidelines is to ensure safe, effective and high-quality medicines are developed and registered efficiently. ICH guidelines are a set of guidances to ensure safe, effective and high-quality medicines are developed and registered efficiently. These guidelines have been adopted by regulatory authorities throughout the world. Aseptic manufacturing is used in cases, where the drug substance is instable against heat, hence sterilisation in the final container closure system is not possible. Aseptic manufacturing means that the used drug substance and excipients were sterilised appropriately and all materials, equipment and container closure systems were used only after sterilisation. All working steps were performed in so called clean areas to avoid contamination. Therefore high standards have to be established concerning the manufacturing room, the personnel, the equipment and the supply systems (air system, water for injection, sterile gases used in the working process; for example compressed air, nitrogen etc.).

Keywords: ICH Guideline, Aseptic Condition, Sterilization

REFERENCES

- [1]. Good Practices for pharmaceutical quality control laboratories. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report. Geneva, World Health Organization. WHO Technical Report Series, No. 957, 2010, Annex 1.
- [2]. General guidelines for the establishment, maintenance and distribution of chemical reference substances. Revision. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report. Geneva, World Health Organization. WHO Technical Report Series, No. 943, 2007, Annex 3.
- [3]. The International Pharmacopoeia, Fourth Edition. Geneva, World Health Organization, 2006. Also available on CD-ROM.
- [4]. The International Pharmacopoeia, Fourth Edition, First Supplement. Geneva, World Health Organization, 2008. Also available on CD-ROM.
- [5]. ISO/IEC 17025 (2005) General requirements for the competence of testing and calibration laboratories.
- [6]. ISO 11133-1 (2000) Microbiology of food and animal feeding stuffs — Guidelines on preparation and production of culture media — Part 1: General guidelines on quality assurance for the preparation of culture media in the laboratory.
- [7]. ISO 13843 (2000) Water quality — Guidance on validation of microbiological methods.
- [8]. ICHQ5A (R1)-viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.
- [9]. ICHQ5b- analysis of the expression construct in cells used for production of R-DNA derived protein products.
- [10]. ICHQ5C-stability testing of biotechnological/biological products.
- [11]. ICHQ5D- derivation and characterization of cell substrates used for production of biotechnological/biological products.
- [12]. ICHQ5E-comparability of biotechnological/biological products subject to changes in their manufacturing process.
- [13]. ICHQ6A-specifications: test procedure and acceptance criteria for new drug substances and new drug products: chemical substances.

- [14]. ICHQ6B-specification: test procedures and acceptance criteria for biotechnological/biological products.
- [15]. ICHQ7-good manufacturing practice guide for active pharmaceutical ingredients.
- [16]. ICHQ8 (R2)-pharmaceutical development
- [17]. ICHQ9-quality risk management
- [18]. ICHQ10-pharmaceutical quality system
- [19]. ICHQ11-development and manufacture of drug substances (chemical entities and bio technological/biological entities.).
- [20]. ICHQ12-technical and regulatory considerations for pharmaceutical product life cycle management.